NCT04893551 - A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 25, 2021

Primary Completion Date

June 27, 2022

Study Completion Date

June 27, 2022

Conditions

Ovarian Neoplasms

Interventions

BIOLOGICAL

Tilvestamab

Tilvestamab will be administered as IV infusion.

Trial Locations (9)

Haukeland University Hospital Bergen, Bergen

National University Hospital, Singapore

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Yonsei University Health System- Severance Hospital, Seoul

Western General Hospital, Edinburgh

Guys and St Thomas' NHS Foundation Trust, London

Imperial College London, Hammersmith Hospital, London

Churchill Hospital, Oxford